A Randomized, Double-Blind Placebo-Controlled Phase 2 Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Efatutazone (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 20 Nov 2013 Planned end date changed from 1 Mar 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
- 16 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 07 Mar 2012 Planned end date changed from 1 Mar 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History